Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.

Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model

Agilent Technologies' (A) fiscal third quarter results reflect growth in pharmaceutical and food market. However, COVID-19 headwinds were concerns.

Agilent's (A) Q3 Earnings Beat Estimates, Revenues Down Y/Y

Agilent Technologies Inc. (A) CEO Mike McMullen on Q3 2020 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 18.18% and 3.90%, respectively, for the quarter ended July 2020. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Beats Q3 Earnings and Revenue Estimates

Agilent Technologies (A) earnings for the R&D company's fiscal third quarter of 2020 have A stock dipping lower after-hours Tuesday.
The post Agilent Technologies Earnings: A Stock Dips 2% Despite Beating Q3 Estimates appeared first on InvestorPlace.

Agilent Technologies Earnings: A Stock Dips 2% Despite Beating Q3 Estimates

Late Tuesday, Agilent Technologies reported earnings and sales that beat Wall Street expectations, even though per-share profit minus items slipped 1%. Agilent stock edged higher marginally.

Agilent Earnings, Sales Beat Wall Street Expectations; Agilent Stock Edges Up

Agilent Technologies Inc. A, +0.32% shares were down 2% in after-hours trading Tuesday after the research, development, and manufacturing company reported fiscal third-quarter results that were roughly in line with Wall Street estimates for earnings but missed on revenue.

Agilent Technologies shares dip 2% on decline in revenue

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces third quarter fiscal year 2020 financial results.

Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to expand state-of-the-art manufacturing capacity for nucleic acid-based therapeutics.

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

Agilent's (A) leadership position and strength in revenue segments are likely to reflect on fiscal third-quarter results. However, the global coronavirus-driven economic crisis may have been a woe.

Agilent (A) Gears Up for Q3 Earnings: What's in the Cards?

Deere & Company

Dollar General

JD.com

Nordson

Expectations for second-quarter earnings as a whole, have improved to some extent from what they were at the beginning of the reporting cycle.

Buy 5 Large-Cap Stocks Ahead of Earnings Results This Month

Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent Technologies (A) Expected to Beat Earnings Estimates: Should You Buy?

Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Agilent Technologies (A)

To build your earnings season watch list, look for stocks in or near a potential buy range ahead of their next report. One company that fits that bill is Agilent.

Agilent Technologies At Upper End Of Buy Range With Earnings Due

Benefitfocus

Cisco Systems

There's much potential in non-FAANG tech stocks waiting to report.

Brokers Recommend These Tech Stocks & So Do We

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to webcast third-quarter financial results conference call August 18.

Agilent to Webcast Third-Quarter Fiscal Year 2020 Financial Results Conference Call

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent (A) Up 9.9% Since Last Earnings Report: Can It Continue?

Agilent isn't exciting, but there's value in stability.

Agilent: Stability In An Unstable World

Agilent (A) recently announces the launch of two products in a bid to expand presence in the Mass Spectrometry market.

Agilent (A) Launches Two Products in Mass Spectrometry

Agilent Technologies, Inc. (A) Management Presents at Jefferies Virtual Healthcare Conference (Transcript)

As of late, it has definitely been a great time to be an investor in Agilent Technologies.

Agilent's Shares March Higher, Can It Continue?

Agilent (A) plans to offer a series of senior notes, subject to market conditions and other factors.

Agilent (A) Announces Proposed Offering of Senior Notes

Agilent Technologies Inc. A, +1.67% said Monday it is offering a series of senior notes in a shelf registration with plans to use any proceeds for general corporate purposes, including to pay down debt.

Agilent files for an offering of senior notes

Agilent's (A) second-quarter fiscal 2020 results reflect negative impact of coronavirus outbreak despite robust performance of the Diagnostics and Genomics Group.

Agilent's (A) Q2 Earnings Beat Estimates, Revenues Down Y/Y

Agilent Technologies' (A) CEO Mike McMullen on Q2 2020 Results - Earnings Call Transcript

News for Agilent Technologies Stock (A)